Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 149,461 | $659K |
| Grant or award | 9 | 585,468 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
34 Form 4 filings on record, the earliest from Nov 20, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jeffrey Silber - Officer | Grant or award | Class A Common Stock | 137,036 | $0.00 | - | |
| Open-market sale | Class A Common Stock | 127,890 | $4.52 | $578K | ||
| Jay Shepard | Grant or award | Class A Common Stock | 63,481 | $0.00 | - | |
| Marla L. Kessler | Grant or award | Class A Common Stock | 63,481 | $0.00 | - | |
| Grant or award | Class A Common Stock | 63,481 | $0.00 | - | ||
| Jon R. Duane | Grant or award | Class A Common Stock | 63,481 | $0.00 | - | |
| Grant or award | Class A Common Stock | 4,065 | $0.00 | - | ||
| Grant or award | Class A Common Stock | 63,481 | $0.00 | - | ||
| Julie McHugh | Grant or award | Class A Common Stock | 63,481 | $0.00 | - | |
| Julie McHugh | Open-market sale | Class A Common Stock | 21,571 | $3.73 | $80K | |
| Catherine Moukheibir | Grant or award | Class A Common Stock | 63,481 | $0.00 | - | |
| Grant or award | Common Stock | 25,000 | $0.00 | - | ||
| Grant or award | Class A Common Stock | 4,451 | $0.00 | - | ||
| Open-market sale | Class A Common Stock | 6,725,000 | $3.05 | $20.51M | ||
| Open-market sale | Class A Common Stock | 5,800 | $3.31 | $19K | ||
| Minardo John - Officer | Grant or award | Class A Common Stock | 136,612 | $0.00 | - | |
| Gregory S. Martini - Officer | Grant or award | Class A Common Stock | 136,612 | $0.00 | - | |
| Grant or award | Class A Common Stock | 136,612 | $0.00 | - | ||
| Michael Shetzline - Officer | Grant or award | Class A Common Stock | 136,612 | $0.00 | - | |
| Grant or award | Class A Common Stock | 163,934 | $0.00 | - | ||
| Grant or award | Class A Common Stock | 409,836 | $0.00 | - | ||
| Minardo John - Officer | Open-market sale | Class A Common Stock | 17,439 | $3.81 | $66K | |
| Minardo John - Officer | Open-market sale | Class A Common Stock | 19,053 | $3.66 | $70K | |
| Michael Shetzline - Officer | Open-market sale | Class A Common Stock | 15,570 | $3.81 | $59K | |
| Michael Shetzline - Officer | Open-market sale | Common Stock | 17,012 | $3.66 | $62K | |
| Open-market sale | Class A Common Stock | 10,287 | $3.81 | $39K | ||
| Open-market sale | Class A Common Stock | 11,239 | $3.66 | $41K | ||
| Open-market sale | Class A Common Stock | 94,757 | $3.81 | $361K | ||
| Open-market sale | Class A Common Stock | 103,526 | $3.66 | $379K | ||
| Gregory S. Martini - Officer | Open-market sale | Class A Common Stock | 10,487 | $3.81 | $40K | |
| Gregory S. Martini - Officer | Open-market sale | Class A Common Stock | 11,457 | $3.66 | $42K | |
| Open-market sale | Class A Common Stock | 11,552 | $3.81 | $44K | ||
| Open-market sale | Class A Common Stock | 12,621 | $3.66 | $46K | ||
| Open-market sale | Class A Common Stock | 35,416 | $4.60 | $163K | ||
| Grant or award | Class A Common Stock | 4,178 | $0.00 | - | ||
| Open-market sale | Class A Common Stock | 6,016 | $3.32 | $20K | ||
| Grant or award | Class A Common Stock | 11,718 | $0.00 | - | ||
| Minardo John - Officer | Open-market sale | Class A Common Stock | 7,754 | $0.84 | $7K | |
| Gregory S. Martini - Officer | Open-market sale | Class A Common Stock | 1,265 | $0.84 | $1K | |
| Open-market sale | Class A Common Stock | 2,846 | $0.84 | $2K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
IRONWOOD PHARMACEUTICALS INC (IRWD) had 9 insider filings in the last 90 days, with the most recent on 2026-07-22. The full record for IRWD runs to 34 Form 4 filings, the earliest from 2024-11-20. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of IRWD were filed in the last 90 days.
2 insider sales of IRWD were filed in the last 90 days, totaling $659K.
This page tracks IRWD Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add IRWD to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.